As one of the third batch of recognized medical institutions for imported Hong Kong and Macau drugs and medical devices (referred to as "Hong Kong Macau Medical Device Connect") in the nine cities of the Guangdong Hong Kong Macau Greater Bay Area, Shenzhen New Frontier United Family Hospital actively introduces innovative drugs and medical devices that have been registered in Hong Kong and Macau and are urgently needed in clinical practice, allowing patients to use advanced treatment plans that are synchronized with international standards as early as possible.

 

Currently, the hospital is usingThe proportion of original drugs to total drugs is about 75%It covers multiple treatment fields such as cancer, cardiovascular disease, allergies, etc. After the implementation of the policy, hospitals will be able to further expand the types of innovative and imported drugs, greatly enriching the medication choices of residents in the Greater Bay Area. At the same time, medical equipment will also be introduced gradually, further improving the quality of diagnosis and treatment and internationalization level.

 

As of July 2025, the hospital has successfully introduced multiple breakthrough drugs through the "Hong Kong Macau Medical Device Connect", covering areas such as tumors, rare diseases, and chronic diseases, further expanding patients' treatment options and improving overall health and well-being.
 

Ruxolitinib Phosphate Cream

• Indications
Vitiligo (the world's first topical application) JAK Inhibitors)

• Clinical efficacy
Can be suppressed JAK1/JAK2 Channels to reduce attacks on melanocytes CD8+T Cells promote the recovery of skin pigmentation. In January 2025, our hospital issued the first prescription for Ms. Xia (with white patches on her face and hands), who showed significant discoloration and avoided the burden of traditional phototherapy and oral medication on her liver and kidneys.

 

Tremelimumab actl (Imjudo)

• Indications
Unresectable hepatocellular carcinoma (first-line immunotherapy)

• Clinical efficacy
According to international treatment guidelines, the combination of this drug and Duvalimumab can stimulate the immune system to produce a "detonator effect" and enhance anti-cancer efficacy. After its introduction by the end of 2024, it has benefited multiple patients and feedback shows a significant improvement in tumor control rate.

 

Plan to apply for drugs and main indications (continuously updated)
 

Dust mite allergen sublingual tablets (ACARIZAX)

• Indications
Used to treat allergic rhinitis (nasal mucosal inflammation) in adults and adolescents (12-65 years old) and dust mite related allergic asthma in adults (18-65 years old)

 

ORALTEK D. PTERONYSSINUS/D. FARINAE SUBLINGUAL SPRAY

• Indications
Suitable for adults and children aged 5 and above, used for the treatment of transdermal prick tests and/or specificity IgE Caused by house dust mites and/or dust mite allergens for experimental diagnosis I Allergic respiratory diseases (IgE mediated), such as allergic rhinitis, allergic conjunctivitis, and/or allergic rhinoconjunctivitis with or without bronchial asthma

 

ORALTEK EPITHELIA SUBLINGUAL SPRAY (FELIS DOMESTICUS)

• Indications

 

ORALTEK EPITHELIA SUBLINGUAL SPRAY (Canis familiaris)

• Indications
Suitable for adults and children aged 5 and above, used for the treatment of transdermal prick tests and/or specificity IgE Diagnosis of canine epithelial (domestic dog) allergens through experimental testing I Allergic respiratory diseases (IgE mediated), such as allergic rhinitis, allergic conjunctivitis, and/or allergic rhinoconjunctivitis with or without bronchial asthma.

 

Policy advantages and services benefiting Hong Kong people

The hospital has established referral channels with Hong Kong Xiyu Cancer Center and Hong Kong Comprehensive Cancer Center to achieve cross-border linkage between Shenzhen and Hong Kong, and supports online multi-disciplinary consultations (MDT), including surgeons, oncologists, and auxiliary medical teams, to strive for golden treatment opportunities for patients.

 

· Insurance direct payment (no need to search for numbers), sign and leave

 

· Competitive drug prices

Relying on the national centralized procurement policy, the prices of some targeted drugs are about one-fifth of the Hong Kong market price, and hospitals have also introduced innovative drugs unique to mainland China (such as sunitinib) to meet personalized treatment needs while significantly reducing medical expenses.

 

Shenzhen New Frontier United Family Hospital will continue to deepen the application of the "Hong Kong Macau Medical Device Connect" policy, actively introduce more special drugs for rare diseases and international cutting-edge medical technologies, further promote the coordinated development of medical care in the Greater Bay Area, and strive to become the preferred platform for Hong Kong people seeking medical treatment in the north.